Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Research & Development (2016 - 2025)

Historic Research & Development for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $27.3 million.

  • Coherus Oncology's Research & Development rose 2358.06% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.2 million, marking a year-over-year increase of 280.58%. This contributed to the annual value of $93.3 million for FY2024, which is 1471.18% down from last year.
  • Per Coherus Oncology's latest filing, its Research & Development stood at $27.3 million for Q3 2025, which was up 2358.06% from $26.3 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Research & Development ranged from a high of $203.5 million in Q1 2021 and a low of $20.6 million during Q2 2024
  • For the 5-year period, Coherus Oncology's Research & Development averaged around $44.4 million, with its median value being $28.4 million (2024).
  • In the last 5 years, Coherus Oncology's Research & Development surged by 51464.95% in 2021 and then tumbled by 5925.29% in 2022.
  • Quarter analysis of 5 years shows Coherus Oncology's Research & Development stood at $50.8 million in 2021, then plummeted by 42.83% to $29.0 million in 2022, then decreased by 9.14% to $26.4 million in 2023, then dropped by 15.57% to $22.3 million in 2024, then rose by 22.41% to $27.3 million in 2025.
  • Its last three reported values are $27.3 million in Q3 2025, $26.3 million for Q2 2025, and $24.4 million during Q1 2025.